Impact of screening on cervical cancer incidence: A population-based case-control study in the United States.
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
Cervical cancer is widely preventable through screening, but little is known about the duration of protection offered by a negative screen in North America. A case-control study was conducted with records from population-based registries in New Mexico. Cases were women diagnosed with cervical cancer in 2006-2016, obtained from the Tumor Registry. Five controls per case from the New Mexico HPV Pap Registry were matched to cases by sex, age and place of residence. Dates and results of all cervical screening and diagnostic tests since 2006 were identified from the pap registry. We estimated the odds ratio of nonlocalized (Stage II+) and localized (Stage I) cervical cancer associated with attending screening in the 3years prior to case-diagnosis compared to women not screened in 5years. Of 876 cases, 527 were aged 25-64years with 3years of potential screening data. Only 38% of cases and 61% of controls attended screening in a 3-year period. Women screened in the 3years prior to diagnosis had 83% lower risk of nonlocalized cancer (odds ratio [OR] = 0.17, 95% CI: 0.12-0.24) and 48% lower odds of localized cancer (OR = 0.52, 95% CI: 0.38-0.72), compared to women not screened in the 5years prior to diagnosis. Women remained at low risk of nonlocalized cancer for 3.5-5years after a negative screen compared to women with no negative screens in the 5years prior to diagnosis. Routine cervical screening is effective at preventing localized and nonlocalized cervical cancers; 3 yearly screening prevents 83% of nonlocalized cancers, with no additional benefit of more frequent screening. Increasing screening coverage remains essential to further reduce cervical cancer incidence.
